TZ-POR 7a

TZ-POR 7a (also referred to as TZD # 7a) is a novel small molecule thiazolidinedione (TZD) derivative designed for the potential treatment of type 2 diabetes. It was developed as a structural modification of pioglitazone, featuring a pyrimidine effector site and a secondary nitrogen atom replacing the ethyl ether linkage. The compound functions as a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, aiming to improve insulin sensitivity and glucose metabolism. Preclinical findings suggest that TZ-POR 7a can reduce basal insulin secretion by approximately 50% while increasing glucose-stimulated insulin secretion by 28%, potentially preventing both fasting hypoglycemia and postprandial hyperglycemia. It also enhances glucose uptake in pancreatic beta cells. Currently, it remains a research compound primarily discussed in academic literature without a commercial sponsor.